Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 4/20 | 0.44 |
| ▸ | CYBB | P04839 | 1/20 | 0.44 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | GABRA1 | P14867 | 5/20 | 0.40 |
| ▸ | GABRA5 | P31644 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | CASP7 | P55210 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 6/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4379935 | 0.81 | MAPK14 (0.43) | NOX4CYBBBRD4GABRA1GABRA5 | |
| SCHEMBL22264250 | 0.79 | ADAMTS4 (0.39) | ALDH1A1 | |
| SCHEMBL29988521 | 0.79 | ADAMTS4 (0.39) | ALDH1A1 | |
| SCHEMBL1861393 | 0.79 | NOX4 (0.43) | NOX4CYBBBRD4GABRA1GABRA5 | |
| SCHEMBL3657215 | 0.76 | TLR7 (0.44) | BRD4 | |
| SCHEMBL4376936 | 0.74 | LMNA (0.52) | NOX4CYBBBRD4GABRA1GABRA5 | |
| SCHEMBL4481745 | 0.74 | ALDH1A1 (0.47) | BRD4ALDH1A1LMNA | |
| SCHEMBL4382982 | 0.74 | MAPK14 (0.51) | GRIN1GRIN2B | |
| SCHEMBL31381681 | 0.74 | PTGS1 (0.34) | — | |
| SCHEMBL3665175 | 0.71 | ALDH1A1 (0.40) | ALDH1A1LMNAKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231653-B1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2013-04-03 | — | — | EP | disclosed |
| US-8299065-B2 | Antibacterial condensed thiazoles | BIOTA EUROPE LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | BIOTA EUROPE LTD (GB) | 2010-12-02 | — | — | US | disclosed |
| EP-2231653-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | Biota Europe Ltd (GB) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009074812-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | PROLYSIS LTD (GB) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305067-A1 | ANTIBACTERIAL CONDENSED THIAZOLES | NEK6, NEK1, TXK | NOX4 238/4885CYBB 330/4885BRD4 478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.